JOP20190233A1 - نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون - Google Patents
نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتونInfo
- Publication number
- JOP20190233A1 JOP20190233A1 JOP/2019/0233A JOP20190233A JOP20190233A1 JO P20190233 A1 JOP20190233 A1 JO P20190233A1 JO P20190233 A JOP20190233 A JO P20190233A JO P20190233 A1 JOP20190233 A1 JO P20190233A1
- Authority
- JO
- Jordan
- Prior art keywords
- benzoazepine
- bruton
- analogs
- tyrosine kinase
- inhibiting agents
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 150000008038 benzoazepines Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
غير متوفر
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485745P | 2017-04-14 | 2017-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190233A1 true JOP20190233A1 (ar) | 2019-10-02 |
Family
ID=62092333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0233A JOP20190233A1 (ar) | 2017-04-14 | 2017-06-16 | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US10227341B2 (ar) |
| EP (2) | EP4249071A3 (ar) |
| JP (2) | JP7145874B2 (ar) |
| KR (2) | KR20230164247A (ar) |
| CN (2) | CN117567453A (ar) |
| AR (1) | AR111594A1 (ar) |
| AU (2) | AU2018253209B2 (ar) |
| BR (1) | BR112019021399A2 (ar) |
| CA (1) | CA3058774A1 (ar) |
| CL (1) | CL2019002900A1 (ar) |
| CO (1) | CO2019012571A2 (ar) |
| CR (1) | CR20190517A (ar) |
| DK (1) | DK3609886T3 (ar) |
| EA (1) | EA201992354A1 (ar) |
| FI (1) | FI3609886T3 (ar) |
| IL (2) | IL294175A (ar) |
| JO (1) | JOP20190233A1 (ar) |
| LT (1) | LT3609886T (ar) |
| MA (1) | MA50013A (ar) |
| MX (1) | MX2023000812A (ar) |
| PE (1) | PE20200740A1 (ar) |
| PH (1) | PH12019502334A1 (ar) |
| SA (1) | SA519410292B1 (ar) |
| SG (1) | SG11201909224QA (ar) |
| TW (2) | TWI790227B (ar) |
| UA (1) | UA127347C2 (ar) |
| WO (1) | WO2018191577A1 (ar) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201908558WA (en) | 2013-12-11 | 2019-10-30 | Biogen Ma Inc | Biaryl Compounds Useful For The Treatment Of Human Diseases In Oncology, Neurology And Immunology |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
| US11820760B2 (en) | 2018-10-15 | 2023-11-21 | Biogen Ma Inc. | Crystalline polymorphs of Bruton's tyrosine kinase inhibitors |
| JP2022532235A (ja) * | 2019-05-15 | 2022-07-13 | バイオジェン・エムエイ・インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| EP4313023A1 (en) * | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| WO2023086521A1 (en) | 2021-11-10 | 2023-05-19 | Biogen Ma Inc. | Btk inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2125819B1 (en) | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| BRPI0817503B8 (pt) | 2007-10-05 | 2021-05-25 | Sstarbio Pte Ltd | derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa |
| WO2009107391A1 (ja) | 2008-02-27 | 2009-09-03 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| CA2986640C (en) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| HUE043522T2 (hu) * | 2009-09-04 | 2019-08-28 | Biogen Ma Inc | Bruton tirozinkináz inhibitorok |
| US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| MY192354A (en) | 2011-07-19 | 2022-08-17 | Merck Sharp & Dohme | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
| TWI638815B (zh) * | 2013-02-15 | 2018-10-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（一） |
| US20140357636A1 (en) | 2013-02-21 | 2014-12-04 | Wayne Rothbaum | Treatment of Skeletal-Related Disorders |
| LT3060550T (lt) | 2013-10-21 | 2019-08-12 | Merck Patent Gmbh | Heteroarilo junginiai, kaip btk inhibitoriai, ir jų panaudojimas |
| SG10201908558WA (en) | 2013-12-11 | 2019-10-30 | Biogen Ma Inc | Biaryl Compounds Useful For The Treatment Of Human Diseases In Oncology, Neurology And Immunology |
| BR112017006305B1 (pt) * | 2014-10-06 | 2024-02-20 | Merck Patent Gmbh | Compostos heteroarila, seus usos, e composição farmacêutica |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
-
2017
- 2017-06-16 JO JOP/2019/0233A patent/JOP20190233A1/ar unknown
-
2018
- 2018-04-13 FI FIEP18721632.0T patent/FI3609886T3/fi active
- 2018-04-13 US US15/952,505 patent/US10227341B2/en active Active
- 2018-04-13 MA MA050013A patent/MA50013A/fr unknown
- 2018-04-13 EA EA201992354A patent/EA201992354A1/ru unknown
- 2018-04-13 AR ARP180100935A patent/AR111594A1/es not_active Application Discontinuation
- 2018-04-13 WO PCT/US2018/027415 patent/WO2018191577A1/en active Application Filing
- 2018-04-13 TW TW107112785A patent/TWI790227B/zh active
- 2018-04-13 SG SG11201909224Q patent/SG11201909224QA/en unknown
- 2018-04-13 CA CA3058774A patent/CA3058774A1/en active Pending
- 2018-04-13 IL IL294175A patent/IL294175A/en unknown
- 2018-04-13 CN CN202311088635.7A patent/CN117567453A/zh active Pending
- 2018-04-13 CN CN201880031744.6A patent/CN110621670B/zh active Active
- 2018-04-13 CR CR20190517A patent/CR20190517A/es unknown
- 2018-04-13 DK DK18721632.0T patent/DK3609886T3/da active
- 2018-04-13 EP EP23187919.8A patent/EP4249071A3/en active Pending
- 2018-04-13 AU AU2018253209A patent/AU2018253209B2/en active Active
- 2018-04-13 LT LTEPPCT/US2018/027415T patent/LT3609886T/lt unknown
- 2018-04-13 IL IL269933A patent/IL269933B/en unknown
- 2018-04-13 JP JP2019555961A patent/JP7145874B2/ja active Active
- 2018-04-13 PE PE2019002016A patent/PE20200740A1/es unknown
- 2018-04-13 UA UAA201911128A patent/UA127347C2/uk unknown
- 2018-04-13 BR BR112019021399A patent/BR112019021399A2/pt active Search and Examination
- 2018-04-13 TW TW111149550A patent/TW202315870A/zh unknown
- 2018-04-13 KR KR1020237040706A patent/KR20230164247A/ko active Application Filing
- 2018-04-13 KR KR1020197032715A patent/KR102607900B1/ko active IP Right Grant
- 2018-04-13 EP EP18721632.0A patent/EP3609886B1/en active Active
- 2018-08-27 US US16/113,455 patent/US10189829B2/en active Active
-
2019
- 2019-08-07 US US16/534,540 patent/US10961237B2/en active Active
- 2019-10-10 SA SA519410292A patent/SA519410292B1/ar unknown
- 2019-10-11 CL CL2019002900A patent/CL2019002900A1/es unknown
- 2019-10-11 MX MX2023000812A patent/MX2023000812A/es unknown
- 2019-10-14 PH PH12019502334A patent/PH12019502334A1/en unknown
- 2019-11-12 CO CONC2019/0012571A patent/CO2019012571A2/es unknown
-
2021
- 2021-02-24 US US17/183,702 patent/US11427577B2/en active Active
-
2022
- 2022-07-22 US US17/871,157 patent/US11858926B2/en active Active
- 2022-08-18 AU AU2022218560A patent/AU2022218560B2/en active Active
- 2022-09-20 JP JP2022148866A patent/JP2022180498A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
| EA201991884A2 (ru) | Ингибиторы g12c kras | |
| PH12016500531A1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
| MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| MX2018004664A (es) | Antagonistas de ep4. | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
| MX2022005951A (es) | Compuestos de pirrolotriazina que actuan como inhibidor de mnk. | |
| NZ712341A (en) | A crystalline form of an anxiolytic compound | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
| EA201792676A1 (ru) | Ингибиторы jak1 |